Biotech company Alcidion Group (ASX:ALC)
has renewed its ongoing support services contract with ACT Health for an additional 2 years.
The contract extension is valued at $1.3 million and effective from 1 January 2021.
It relates to the provision of integrated patient management system services.
Managing Director of Alcidion, Kate Quirke, says the company is “proud of [its] longstanding relationship with ACT Health and look[s] forward to providing ongoing technical support services that will support ACT Health’s ongoing commitment to providing highly integrated healthcare across all its facilities in Canberra”.
Shares in Alcidion Group (ASX:ALC)
are trading 3.3 per cent higher at $0.15.